ClinicalTrials.gg
RecruitingNCT07201909CALMUpdated Mar 13, 2026

CALM Study: Can A Prebiotic Fibre bLend Improve Stress, Mood, and Anxiety?

An interventional study of Prebiotic fibre blend and Maltodextrin powder in Stress, sponsored by Myota GmbH. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Myota GmbH · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This clinical trial will investigate whether a powdered prebiotic fibre blend can improve perceived stress levels in healthy adults with mild-severe stress levels.

Read the detailed description

There is growing interest in how the gut microbiota interacts with the brain to influence psychological outcomes, particularly stress. Even in otherwise healthy individuals, persistent psychological stress is associated with measurable physiological changes-including elevated cortisol levels, heightened hypothalamic-pituitary-adrenal (HPA) axis reactivity, and systemic low-grade inflammation. These biological signatures are increasingly understood to be shaped, in part, by the composition and activity of the gut microbiota.

In this study, we're investigating how a powdered prebiotic fibre supplement can improve stress levels. You may have heard people refer to this as the 'gut-brain axis'. We'll also be looking at the link between the prebiotic fibre supplement intake and changes in other areas of health, like depression, mood, anxiety, cognition, inflammation, and the gut microbiome.

02

Conditions studied

  • Stress

Browse trials for

Keywords

  • gut-brain axis
  • perceived stress
  • prebiotic fibre
  • cognitive function
  • anxiety
  • mood
  • depression
  • inflammation
03

In context

Anxiety Disorders Unverified

7,238 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 156 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Myota GmbH is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-50 years of age
  • Capacity to give to participate in the study
  • Able to comply with study requirements and visits
  • Meet the range required for mild-severe stress levels (as assessed by DASS-42 stress subscale)
  • Normal or corrected to normal vision and/or hearing

Exclusion criteria

Exclusion Criteria:

  • Current smoker
  • Having food allergies and/or intolerances
  • Diagnosis of Type 1 or 2 diabetes or cardiovascular disease or psychiatric or neurological conditions (e.g. schizophrenia, dementia) including eating disorders
  • Current or previous diagnosis of depression in past 6 months
  • Receiving medications that lower cholesterol, blood pressure, blood glucose levels, or improve insulin sensitivity
  • Receiving antidepressant or anti-anxiety medications or treatments
  • Receiving hormonal
  • Perimenopause or menopause
  • Pregnancy, lactation, or an intent to become pregnant during the course of the study
  • Continuous antibiotic use for > 3 days within 1 month prior to enrolment
  • Continuous use of weight-loss drug for > 1 month before screening
  • Major change in dietary intake in past month (e.g. excluding whole food groups)
  • Currently consuming daily prebiotic or probiotic supplements
  • Prior use (\< 6 months) of any blood glucose or cholesterol lowering medication
  • Any significant GI condition affecting GI absorption including (but not limited to) inflammatory bowel disease, weight loss surgery, irritable bowel disease.
  • End stage renal disease
  • Active cancer, or treatment for any cancer, in last 3 years
  • Consuming more than 20g of fibre a day as assessed by the 18-item FiberScreen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Prebiotic fibre blend

    Prebiotic fibre blend, consisting of 10g of a powdered supplement, to be taken daily alongside usual diet for 12 weeks.

    Dietary Supplement: Prebiotic fibre blend

  • Placebo comparator
    Placebo

    Placebo will be 10g of maltodextrin powder, to be taken daily alongside usual diet for 12 weeks.

    Dietary Supplement: Maltodextrin powder

Interventions

  • Dietary supplementPrebiotic fibre blend

    A blend of prebiotic fibres in a powdered supplement form.

  • Dietary supplementMaltodextrin powder

    Maltodextrin powder

06

What researchers measure

Primary outcomes

  1. Perceived Stress

    The primary objective is to determine the effect of 12-week long daily administration of Prebiotic fibre blend as compared to Placebo on stress scores (Perceived Stress Scale) on a scale between 0 - 40 (where higher scores indicate higher stress).

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Perceived Stress

    To determine the effect of 12-week long daily administration of Prebiotic fibre blend as compared to Placebo on stress scores (Perceived Stress Scale) on a scale between 0 - 40 (where higher scores indicate higher stress).

    Time frame: Baseline and 8 weeks

  2. Depression

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on depression scores (DASS-42), on a scale between 0 - 21 (where higher scores mean higher depression).

    Time frame: Baseline, 8 weeks, and 12 weeks

  3. Mood

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on mood scores (PANAS-X), on a scale between 10 - 50 (where higher scores on the Positive Affect scale indicate higher levels of positive engagement with your environment; while higher scores on the Negative Affect scale indicate higher levels of negative engagement).

    Time frame: Baseline, 8 weeks and 12 weeks

  4. Anxiety

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on anxiety scores (DASS-42), on a scale between 0 - 21 (where higher scores mean higher anxiety levels).

    Time frame: Baseline, Week 8, and Week 12

  5. Serum hs-CRP

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum high sensitivity C-Reactive Protein (hs-CRP).

    Time frame: Baseline and Week 12

  6. Gastrointestinal symptoms

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on gastrointestinal symptoms (GSRS), on a scale of 15 - 105 where higher scores indicate more severe gastrointestinal discomfort.

    Time frame: Baseline, Week 8, and Week 12

  7. Cognition: Emotional Stroop

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on emotional interference in attention and processing (reaction time and accuracy), as assessed by the Emotional Stroop where better scores are achieved by lower reaction times and higher accuracy score.

    Time frame: Baseline and Week 12

  8. Cognition: Affective 2-Back Task

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on emotional interference in working memory under emotional load, as assessed by the Affective 2-Back Task, where better scores are achieved by lower reaction times and higher accuracy score.

    Time frame: Baseline and Week 12

  9. Cognition: Emotional Go-No-Go

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on emotion-related inhibitory control and response suppression, as assessed by the Emotional Go-No-Go, where better scores are achieved by higher correct response rates and lower commission errors.

    Time frame: Baseline and Week 12

  10. Cognition: Number-Letter Task

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on cognitive flexibility and task-switching ability, as assessed by the Number-Letter Task, where better scores are achieved by higher numbers of correctly recalled items.

    Time frame: Baseline and Week 12

  11. Cognition: Attentional Network Task

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on efficiency of alerting, orienting, and executive attention networks, as assessed by the Attentional Network Task , where better scores are achieved by lower reaction times and higher accuracy.

    Time frame: Baseline and Week 12

Other outcomes

  1. Sleep Quality

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on sleep quality (PSQI), on a scale of 0 - 21 where higher scores indicate worse sleep.

    Time frame: Baseline and Week 12

  2. Quality of Life Index

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on quality of life index (WHOQOL), on a scale of 0 -100 where higher scores indicate higher quality of life.

    Time frame: Baseline And Week 12

  3. Serum LDL Cholesterol

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum LDL cholesterol.

    Time frame: Baseline and Week 12

  4. Serum HDL Cholesterol

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum HDL cholesterol.

    Time frame: Baseline and Week 12

  5. Serum Triglycerides

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum triglycerides.

    Time frame: Baseline and Week 12

  6. Total cholesterol

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum total cholesterol.

    Time frame: Baseline and Week 12

  7. Waist to hip ratio

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on waist to hip ratio.

    Time frame: Baseline and Week 12

  8. Waist circumference

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on waist circumference (cm).

    Time frame: Baseline and Week 12

  9. Gut microbiome composition

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on gut microbiome diversity scores (alpha and beta measures) and composition (differential abundance testing).

    Time frame: Baseline and Week 12

  10. Systolic blood pressure

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on systolic blood pressure (mmHg).

    Time frame: Baseline and Week 12

  11. Diastolic blood pressure

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on diastolic blood pressure (mmHg).

    Time frame: Baseline and Week 12

  12. BMI

    To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on BMI (kg/m2).

    Time frame: Baseline and Week 12

  13. Exploratory endpoint

    Inter-dependencies between primary and secondary outcomes will be assessed.

    Time frame: Baseline, Week 8, and Week 12

07

Study locations

1 of 1 sites recruiting
  • CALM Study Site
    London, EC2A 4BQ, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Participant data will not be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

Of 105 industry-sponsored interventional studies with no phase under Anxiety Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's planned 11 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Oct 1, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07201909
Lead sponsor
Myota GmbH
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Oct 2, 2025
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 13, 2026

Study contacts

Caitlin Hall, PhD, RD
Contact
caitlin@myotahealth.com
07830709854

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion